Continuous production technology innovation: industry accelerates towards efficient and low-carbon production mode
Release time:
2025-03-01
Source:
According to the International Energy Agency (IEA) report Energy Efficiency 2023, the industrial sector accounts for 37% of global energy consumption and 24% of carbon emissions, while traditional batch production processes exhibit energy waste rates as high as 35%-40%.
According to the International Energy Agency (IEA) report Energy Efficiency 2023, the industrial sector accounts for 37% of global energy consumption and 24% of carbon emissions, while traditional batch production processes exhibit energy waste rates as high as 35%-40%. The report highlights that companies adopting continuous flow technology can reduce energy consumption per unit output by 30% and improve material utilization from 78% (traditional processes) to over 94%. For example, in the chemical industry, continuous flow microreactors achieve a 50% increase in reaction efficiency and a 60% reduction in waste generation through precise temperature and pressure control (Source: IEA Report, Section 4.2).
Accenture's 2023 Industrial Technology Innovation Trends Survey reveals that 83% of chemical and pharmaceutical companies have prioritized continuous flow technology in their strategies. By integrating Process Analytical Technology (PAT) and automated control systems, this technology reduces production cycles by 70% and labor costs by 45%. For instance, a global Top 10 pharmaceutical company reduced active pharmaceutical ingredient (API) production costs by 28%, cut annual carbon emissions by 12,000 metric tons, and achieved a payback period of just 14 months after adopting continuous flow crystallization equipment (Source: Accenture Report, Case Study Section).
The U.S. FDA mandates the prioritization of continuous flow technology for pharmaceutical manufacturers in its Guidance for Industry: Continuous Manufacturing. According to Grand View Research, the global pharmaceutical continuous flow equipment market reached **1.98billionin2023∗∗,witha∗∗21.47.6 billion by 2030**. Case studies demonstrate that continuous flow processes compress drug production timelines from 90 days (traditional batch) to 7 days, while reducing product deviation rates from **±5% to ±0.5% (Source: FDA Guidance Section III.B and Grand View Research Market Report).
Note:
The reports above are sourced from third-party institutions, and some content may require registration to download. For our company’s proprietary analysis report on continuous flow technology, please contact the Marketing Department.
Other News
Advancing Continuous Flow Chemistry Solutions
CONTACT US
No. 60, Yunjing East Road, Liyuan Town, Tongzhou District, Beijing City, China